Boehringer Ingelheim Halts Development of HCV Treatment

Drug Industry Daily
A A
Boehringer Ingelheim is halting development of deleobuvir-containing hepatitis C (HCV) drugs after Phase III clinical trial data showed the candidate lacked therapeutic value, clearing away one more candidate from the crowded field of new HCV treatments.

To View This Article:

Login

Subscribe To Drug Industry Daily